Late Breaking Clinical Research

Research accepted for presentation will be: 

• Select clinical trials presented during the Late Breaking Clinical Research plenary session
• Timely clinical research will be spotlighted for short oral presentations during HFSA Spotlight/ Rapid Fire Abstracts session
• JCF encourages all accepted Late Breaking Clinical Research submitters to submit full papers for further consideration
• All late breaking data is embargoed subject to the HFSA policy below

Late breaking clinical research abstracts accepted for plenary sessions and Rapid Fire Oral Abstract sessions are strictly embargoed for release until the time of presentation at the Heart Failure Society of America’s Annual Scientific Meeting. Press releases may not be issued publicly in advance of the embargo. 

Press Access Window

To facilitate accurate and timely reporting, HFSA will provide credentialed and registered media with embargoed access to late-breaking science materials beginning 24 hours before the embargo lifts. 

• During this 24-hour window, journalists may access embargoed press releases, abstracts, and presenter information through a secure, password-protected folder managed by HFSA. 
• Pre-embargo interviews with late-breaking science presenters may be scheduled during this time. 
• Presenters may share approved embargoed institutional press releases with registered media during this period, provided the embargo date and time are clearly stated.* Please send your releases to [email protected] to have your press release reviewed and included in the password-protected press access folder. 
• Presenters may arrange interviews directly with registered media during the press access window, provided the embargo date and time are clearly stated and HFSA is notified.* 
• All materials and interviews remain strictly embargoed until the official presentation time. 

*HFSA does not share the full list of registered journalists, as this information is considered confidential and helps us maintain strong relationships with the press. However, we will share which major outlets are credentialed for ASM 2026 (e.g., The New York Times, MedPage Today, Cardiology Today, etc.) and can help facilitate connections with reporters when appropriate. Presenters are also welcome to work with their institution’s press office to distribute HFSA-approved embargoed releases and arrange pre-embargo interviews directly with journalists, provided the embargo is respected. 

Media Outreach by Presenters 

• Presenters may arrange interviews directly with registered journalists during the 24-hour press access window, provided embargo rules are respected. 
• HFSA will not share the full list of registered journalists. However, HFSA may share which major outlets are credentialed (e.g., The New York Times, MedPage Today, Cardiology Today) and can facilitate introductions to reporters when appropriate. 
• Institutional press offices may distribute HFSA-approved embargoed releases during the 24-hour window, but not before. Please send your releases to [email protected] to have your press release reviewed and included in the password-protected press access folder. 

Permissible Pre-Embargo Announcements

 Prior to the embargo lifting, only the following information may be announced publicly: 

• That the trial is completed. 
• That results will be presented on [date/time] at HFSA ASM. 
• What the trial assessed (basic design, questions, study population, interventions, etc.). 

No results or any indirect reference to results may be included in announcements prior to the time of presentation. 

After the Embargo Lifts

At the time of abstract presentation and anytime thereafter, researchers, authors, universities, medical institutions and health care organizations involved in the study may issue press releases and announcements to the public and media.

Sharing Your News with ASM Registered Media 

To ensure that your Late Breaking Clinical Research release is brought to the attention of registered media and included in communications to registered press, please send your news release for a Late Breaking Clinical Research abstract being presented at ASM to [email protected]. In the body of the email, please include the following: 

• The full name of the abstract; 
• The first and last authors’ names as they are listed on the abstract;  
• The first and last name(s) of the main press contact(s) for this trial/research;  
• The first and last name(s) and role(s) of individuals who will speak to press on behalf of the trial/research; 
• Headshots of lead investigators and/or any supporting illustrations, graphics, tables, etc.; and 
• If it is being published in a scientific journal, please include the name of the journal where it is being published or the name of the meeting where it will be presented, and the date/time of the anticipated publication. 
   

Clinical research accepted for presentation will be: 

• Either presented during the Late Breaking Clinical Research session
• Or presented during a Rapid Fire Spotlight Oral session

Notifications for Late Breaking Clinical Research will be sent by early August. Information on sessions and how to upload slides will be posted here and sent by mid-August.

If an accepted late breaking clinical trial abstract was submitted and accepted for general abstract/poster presentation at the HFSA Annual Scientific Meeting, it needs to be withdrawn by September 1, 2026.